Published: 2 March 2023
Publications
Recent approvals: new active ingredients or new indications
Published: 2 March 2023
Prescriber Update 44(1): 15
March 2023
For the period 16 October 2022 to 15 January 2023.
Recent approvals of medicines with new active ingredients
| Trade name (active ingredient) |
Dose form and strength(s) | Therapeutic area |
|---|---|---|
| Luxturna (voretigene neparvovec) |
Concentrate for injection: 5x10^12 VP/mL | Inherited retinal dystrophy caused by pathological biallelic RPE65 mutations |
Approved medicines with new indications
| Trade Name (active ingredient) |
Dose form and strength(s) | New therapeutic area(s) |
|---|---|---|
| Nucala (mepolizumab) |
Powder for injection: 100 mg/mL Solution for injection (pre-filled pen and pre-filled syringe): 100 mg/mL | Chronic rhinosinusitis with nasal polyps
Hypereosinophilic syndrome |
See the Medsafe website for:
